New Delhi: Pune-based vaccine major Serum Institute of India is planning to start production of the COVID-19 vaccine developed by Oxford University in the next two to three weeks. Not only that, it is also hoping to bring it to the market by October if the human clinical trials are successful. Also Read - Coronavirus in India May 12, 2021 LIVE Updates: Harsh Vardhan to Hold Meeting With States Lagging Behind in Vaccination

“Our team has been working closely with Dr Hill from Oxford University, and we are expecting to initiate production of the vaccine in 2-3 weeks and produce 5 million doses per month for the first 6 months, following which, we hope to scale up production to 10 million doses per month,” Serum Institute India (SII) CEO Adar Poonawalla said. Also Read - IPL 2021: England Players Unlikely To Play In Rescheduled IPL, Feels Michael Atherton

“We expect the (COVID-19) vaccine to be out in the market by September – October, only if the trials are successful with the requisite safety and assured efficacy. We will be starting trials in India for this vaccine hopefully over the next 2-3 weeks’ time,” Poonawalla said. Also Read - IPL 2021: Michael Hussey Tests Positive For Covid-19 Again

“Following that, we have undertaken the decision to initiate manufacturing at our own risk. The decision has been solely taken to have a jump-start on manufacturing, to have enough doses available, if the clinical trials prove successful,” Poonawalla said.

Notably, the Pune-based company has partnered with Oxford University as one of the seven global institutions manufacturing the vaccine.

In the past, SII had collaborated with scientists at Oxford University for a malaria vaccine project.

The company plans to initiate the trials in India for the vaccine with necessary regulatory approvals, which are underway presently.